Frontiers in Molecular Biosciences,
Год журнала:
2024,
Номер
11
Опубликована: Авг. 15, 2024
Inositol
1,4,5-Trisphosphate
Receptor-Interacting
Protein-Like
1
(ITPRIPL1),
a
single-pass
type
I
membrane
protein
located
in
the
membrane,
functions
as
an
inhibitory
ligand
of
CD3ε.
Recent
studies
have
shown
that
its
expression
suppresses
T
cells
activation
and
promote
tumor
immune
evasion.
Despite
increasing
evidence
suggesting
ITPRIPL1
plays
significant
role
growth,
no
systematic
pan-cancer
analysis
has
been
conducted
to
date.
This
study
utilized
datasets
curated
from
The
Cancer
Genome
Atlas,
Genotype
Tissue-Expression,
Human
Protein
Atlas
investigate
relationship
between
clinical
outcomes,
infiltration,
drug
sensitivity
across
33
cancer
types.
We
employed
multiple
methods
assess
prognostic
value
pan-cancer,
such
univariate
Cox
regression,
survival
analysis,
ROC
curve
explored
mutation
burden
(TMB),
microsatellite
instability
(MSI),
CNV,
DNA
methylation,
immune-related
genes,
cell
reveal
immunological
role.
mRNA
levels
gene
vary
significantly
types
reduced
breast
cancer.
Conversely,
high
was
associated
with
better
prognosis
BRCA.
Furthermore,
highly
correlates
presence
tumor-infiltrating
checkpoint
genes
various
cancers.
Additionally,
TMB
6
MSI
13
High
serves
protective
factor
certain
types,
correlating
longer
overall
Our
further
confirms
participates
regulating
infiltration
affecting
patients
pan-cancer.
These
findings
underscore
promising
potential
therapeutic
target
for
human
Cancers,
Год журнала:
2024,
Номер
16(17), С. 2975 - 2975
Опубликована: Авг. 27, 2024
Malignant
gliomas
present
great
difficulties
in
treatment,
with
little
change
over
the
past
30
years
median
survival
time
of
15
months.
Current
treatment
options
include
surgery,
radiotherapy
(RT),
and
chemotherapy.
New
therapies
aimed
at
suppressing
formation
new
vasculature
(antiangiogenic
treatments)
or
destroying
formed
tumor
(vascular
disrupting
agents)
show
promise.
This
study
summarizes
existing
knowledge
regarding
processes
by
which
glioblastoma
(GBM)
tumors
acquire
resistance
to
antiangiogenic
treatments.
The
discussion
encompasses
activation
redundant
proangiogenic
pathways,
heightened
cell
invasion
metastasis,
induced
hypoxia,
creation
vascular
mimicry
channels,
regulation
immune
microenvironment.
Subsequently,
we
explore
potential
strategies
overcome
this
resistance,
such
as
combining
other
methods,
personalizing
treatments
for
each
patient,
focusing
on
therapeutic
targets,
incorporating
immunotherapy,
utilizing
drug
delivery
systems
based
nanoparticles.
Additionally,
would
like
discuss
limitations
methods
future
directions
enhance
beneficial
effects
patients
GBM.
Therefore,
review
aims
research
outcome
GBM
provide
a
more
promising
opportunity
thoroughly
exploring
mechanisms
investigating
novel
strategies.
EMBO Molecular Medicine,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 16, 2025
Abstract
The
gut
microbiome,
or
the
community
of
microorganisms
residing
in
gastrointestinal
tract,
has
emerged
as
an
important
factor
breast
cancer
etiology
and
treatment.
Specifically,
impact
bacterial
populations
on
therapeutic
outcomes
is
emerging
area
research.
microbiota’s
role
modifying
pharmacokinetics
chemotherapy
endocrine-targeting
therapies
can
alter
drug
efficacy
toxicity
profiles.
In
addition,
microbiome’s
capacity
to
regulate
systemic
inflammation
immune
responses
may
influence
effectiveness
both
conventional
immunotherapeutic
strategies
for
treatment
cancer.
Overall,
while
bidirectional
interactions
between
microbiome
are
still
being
studied,
its
increasingly
recognized.
Future
research
provide
more
definitive
insights
help
develop
personalized
harness
improve
outcomes.
Biomedicines,
Год журнала:
2025,
Номер
13(1), С. 216 - 216
Опубликована: Янв. 16, 2025
Background:
Brain
cancers
represent
a
formidable
oncological
challenge
characterized
by
their
aggressive
nature
and
resistance
to
conventional
therapeutic
interventions.
The
tumor
microenvironment
has
emerged
as
critical
determinant
of
progression
treatment
efficacy.
Within
this
complex
ecosystem,
microglia
macrophages
play
fundamental
roles,
forming
intricate
networks
with
peripheral
immune
cell
populations,
particularly
T
cells.
precise
mechanisms
underlying
microglial
interactions
cells
contributions
immunosuppression
remain
incompletely
understood.
Methods:
This
review
comprehensively
examines
the
cellular
dialogue
between
in
two
prominent
brain
malignancies:
primary
glioblastoma
secondary
metastases.
Results:
Through
comprehensive
current
scientific
literature,
we
explore
nuanced
through
which
microglial-T
modulate
growth
responses.
Conclusions:
Our
analysis
seeks
unravel
communication
pathways
that
potentially
underpin
progression,
ultimate
goal
illuminating
novel
strategies
for
cancer
intervention.
Abstract
Interleukin‐23
(IL‐23)
is
a
dominant
cytokine
in
psoriasis,
chronic
inflammatory
skin
disease
that
severely
diminishes
patients'
quality
of
life
and
reduces
lifespan
by
up
to
10
years.
Despite
therapeutic
advancements,
psoriasis
remains
clinical
challenge
due
the
absence
definitive
cure,
treatment
side
effects,
substantial
economic
burden.
Notably,
no
small
molecule
inhibitors
(SMIs)
directly
targeting
IL‐23
have
been
developed
date,
leaving
critical
gap
current
therapies.
In
this
study,
SMIs
emerged
as
promising
alternatives.
A
high‐throughput
virtual
screening
1.57
million
molecules
was
conducted,
followed
molecular
docking
dynamics
(MD)
simulations
(1,
10,
100
ns)
identify
potential
candidates.
Machine
learning‐based
binary
QSAR
models
MetaCore
analysis
established
relevance
these
hits
other
diseases.
As
result,
tenapanor
(MM/GBSA
score:
−101.66
kcal/mol)
ChemBridge
ID
7740
360118
(−101.59
kcal/mol,
−91.003
top
candidates,
demonstrating
exceptional
binding
affinity
stability
100‐ns
simulations.
These
represent
leads,
offering
an
alternative
existing
biologics.
Further
vitro
vivo
validation
will
be
essential
confirm
their
efficacy
first
IL‐23‐targeted
Cancers,
Год журнала:
2025,
Номер
17(5), С. 880 - 880
Опубликована: Март 4, 2025
Cancer
remains
a
significant
public
health
issue
worldwide,
standing
as
primary
contributor
to
global
mortality,
accounting
for
approximately
10
million
fatalities
in
2020
[...].
Cells,
Год журнала:
2025,
Номер
14(5), С. 382 - 382
Опубликована: Март 5, 2025
The
peremptory
need
to
circumvent
challenges
associated
with
poorly
differentiated
epithelial
endometrial
cancers
(PDEECs),
also
known
as
Type
II
(ECs),
has
prompted
therapeutic
interrogation
of
the
prototypically
intractable
and
most
prevalent
gynecological
malignancy.
PDEECs
account
for
cancer-related
mortalities
due
their
aggressive
nature,
late-stage
detection,
poor
response
standard
therapies.
are
characterized
by
heterogeneous
histopathological
features
distinct
molecular
profiles,
they
pose
significant
clinical
propensity
rapid
progression.
Regardless
complexities
around
PDEECs,
still
being
administered
inefficiently
in
same
manner
clinically
indolent
readily
curable
type-I
ECs.
Currently,
there
no
targeted
therapies
treatment
PDEECs.
realization
new
options
transformed
our
understanding
enabling
more
precise
classification
based
on
genomic
profiling.
transition
from
a
provided
critical
insights
into
underlying
genetic
epigenetic
alterations
these
malignancies.
This
review
explores
landscape
focus
identifying
key
subtypes
mutations
that
variants.
Here,
we
discuss
how
correlates
outcomes
can
refine
diagnostic
accuracy,
predict
patient
prognosis,
inform
strategies.
Deciphering
underpinnings
led
advances
precision
oncology
protracted
remissions
patients
untamable
